Vireo Growth (VREOF) Total Non-Current Liabilities (2021 - 2026)

Vireo Growth (VREOF) reported Total Non-Current Liabilities of $604.7 million for Q1 2026, up 166.89% on a YoY basis from $226.6 million in Q1 2025, and up 19.08% sequentially from $507.8 million in Q4 2025.

Vireo Growth (VREOF) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

Vireo Growth (VREOF) has 6 years of Total Non-Current Liabilities data on file, last reported at $604.7 million in Q1 2026.

  • For the quarter ending Q1 2026, Total Non-Current Liabilities rose 166.89% year-over-year to $604.7 million; the trailing twelve-month figure through Mar 2026 stood at $604.7 million (up 166.89% YoY), and the FY2025 full-year result was $507.8 million, up 127.41% from the prior year.
  • Total Non-Current Liabilities rose to $604.7 million in Q1 2026, from $507.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $604.7 million in Q1 2026 to a low of $155.7 million in Q4 2022.
  • A 5-year average of $286.3 million and a median of $217.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • Across the five-year window, Total Non-Current Liabilities gained 6.14% in 2025 and surged 166.89% in 2026, its largest moves.
  • Tracing VREOF's Total Non-Current Liabilities over 5 years: stood at $155.7 million in 2022, then gained by 27.92% to $199.2 million in 2023, then climbed by 12.11% to $223.3 million in 2024, then surged by 127.41% to $507.8 million in 2025, then climbed by 19.08% to $604.7 million in 2026.
  • Business Quant data shows VREOF's Total Non-Current Liabilities at $604.7 million in Q1 2026, $507.8 million in Q4 2025, and $431.5 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 18.28 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 599.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 6.26 Bn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn 604.70 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 604.70 Mn
Dec 31, 2025 507.80 Mn
Sep 30, 2025 431.51 Mn
Jun 30, 2025 380.13 Mn
Mar 31, 2025 226.57 Mn
Dec 31, 2024 223.30 Mn
Sep 30, 2024 204.66 Mn
Jun 30, 2024 217.04 Mn
Mar 31, 2024 213.46 Mn
Dec 31, 2023 199.19 Mn
Sep 30, 2023 184.29 Mn
Jun 30, 2023 173.66 Mn
Dec 31, 2022 155.71 Mn
Sep 30, 2021 110.17 Mn
Jun 30, 2021 52.73 Mn
Mar 31, 2021 58.01 Mn